by Peter Ciszewski | Nov 9, 2021
The U.S. Food and Drug Administration (FDA) has approved the use of miltefosine (Impavido) for the treatment of invasive candidiasis, a rare bloodstream infection. Invasive candidiasis, or systemic candidiasis, is the most serious form of candidiasis. This rare...
by Peter Ciszewski | Nov 9, 2021
Jennifer Gudeman, PharmD, Vice President of Medical and Clinical Affairs at Avadel Pharmaceuticals, discusses the post hoc analyses of data from the REST-ON clinical trial of FT218, an investigational treatment for narcolepsy. Narcolepsy is a rare neurological...
by Peter Ciszewski | Nov 8, 2021
Craig Martin, CEO of Global Genes, discusses the organization’s recent collaboration with the Rare Disease Diversity Coalition (RDDC) on the upcoming RARE Health Equity Summit, being held November 17-19, 2021. As Mr. Martin explains, the...
by Peter Ciszewski | Nov 5, 2021
Samantha Masterson, CEO and President of Myasthenia Gravis Foundation of America (MGFA), discusses the organization’s mission and areas of focus. Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles....
by Peter Ciszewski | Nov 4, 2021
Ashish Pradhan, MD, Executive Director and Disease Area Lead at Genentech, discusses subgroup analysis data of 2-hour ocrelizumab infusions for the treatment of minority group members with relapsing multiple sclerosis (RMS) and primary progressive multiple...
